All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Lenalidomide Plus Rituximab Elicits Prolonged Responses in Mantle Cell Lymphoma

November 20th 2023

Initial induction therapy with the immunomodulatory agent lenalidomide plus the anti-CD20 monoclonal antibody rituximab led to prolonged, durable responses with a manageable safety profile in patients with previously untreated mantle cell lymphoma.

Tebentafusp Sustains OS Benefit in Previously Untreated, Metastatic Uveal Melanoma

November 20th 2023

Paul Nathan, MBBS, PhD, MRCP, discusses the differences between cutaneous melanoma and uveal melanoma that have led to unique unmet needs for patients with the latter malignancy; updated findings from the IMCgp100-202 trial; and how these findings may influence future clinical practice.

Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy

November 19th 2023

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

CAR-M Therapy CT-0508 Shows Promise in HER2-Overexpressing Recurrent/Metastatic Solid Tumors

November 19th 2023

The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.

New RNA-based Therapy Combats Melanoma in Mouse Models

November 18th 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS

November 18th 2023

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.

KB-0742 Exhibits Tolerable Safety and Activity in Relapsed/Refractory Solid Tumors

November 17th 2023

The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675).

Novel Cellular Therapies Aim to Address Off-Tumor, On-Target Toxicities in NSCLC

November 17th 2023

Ben Creelan, MD, discusses several of the methods evaluating cellular therapies currently in the works across the non–small cell lung cancer field.

Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer

November 17th 2023

The emerging CDH6-directed antibody-drug conjugate raludotatug deruxtecan had a manageable safety profile, generated pharmacokinetic activity, and produced early evidence of clinical response in patients with heavily pretreated, platinum-resistant ovarian cancer.

Study Shows Feasibility of IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC

November 17th 2023

Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.

Zanubrutinib Plus Obinutuzumab Gets EU Approval for R/R Follicular Lymphoma

November 17th 2023

The European Commission has granted marketing authorization to the combination of zanubrutinib and obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of systemic therapy.

Mount Sinai Launches Clinic to Help Breast Cancer Patients in Need of Legal Services

November 17th 2023

The Mount Sinai Medical Legal Partnership, which provides legal aid to Mount Sinai Health System patients in need, has launched a clinic to help breast cancer patients navigate legal issues that arise due to their diagnoses.

FDA Approval of Fruquintinib Expands Later-Line Treatment Options in mCRC

November 17th 2023

John Lindsay Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.

FDA Approves Enzalutamide for nmCSPC With High-Risk Biochemical Recurrence

November 17th 2023

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

November 16th 2023

The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents

November 16th 2023

Gaby Hobbs, MD, discusses how research into the biology of myelofibrosis has propelled the development of novel therapies for this patient population and highlights the role that biomarkers play in the diagnosis, prognosis, and treatment response evaluation for these patients.

Olaparib With/Without Cediranib Does Not Improve OS Vs Chemo in Recurrent Platinum-Sensitive Ovarian Cancer

November 16th 2023

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival benefit compared with standard-of-care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.

Masofaniten Plus Enzalutamide Demonstrates Safety and Durable Responses in mCRPC

November 16th 2023

Masofaniten administered in combination with enzalutamide (Xtandi) was tolerable, pharmacokinetically active, and led to a decrease in prostate-specific antigen levels at the recommended phase 2 dose in patients with metastatic castration-resistant prostate cancer.

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Unresectable HER2– Gastric/GEJ Adenocarcinoma

November 16th 2023

The FDA has approved pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Dual-Action Drug Produces Positive Results in Patients With Advanced Neuroendocrine Tumors, Trial Finds

November 16th 2023

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.